Compare Jones Lang LaSalle Inc (JLL) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jones Lang LaSalle Inc vs Moderna, Inc. — how do they compare? Jones Lang LaSalle Inc trades at $360.65 (market cap $16.72B), while Moderna, Inc. trades at $61.2 (market cap $24.18B). The key difference: Moderna, Inc. is the larger of the two by market cap, and Jones Lang LaSalle Inc is trading nearer its 52-week high, Moderna, Inc. nearer its low. Which is the better fit depends on your goals.
| JLL | MRNA | |
|---|---|---|
Market Cap | $16.72B | $24.18B |
Sector | Real Estate | Health |
52-Week High | $373.24 | $81.80 |
52-Week Low | $280.16 | $22.36 |
Enterprise Value | $19.48B | $20.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JLL trades at $363.49, up 1.72% today, near its 52-week high. The stock exhibits bullish technical signals with a golden cross and strong momentum, supported by consistent earnings beats in recent quarters. Revenue grew to $26.12B in 2025, with net income margin improving to 3.64%. Analyst consensus is bullish with a $391.50 price target, and institutional holdings show confidence from firms like Bank of America.
Outlook remains positive driven by earnings growth and operational strength, but risks include economic sensitivity and competitive pressures. The stock offers upside to consensus targets, though valuation metrics like P/E of 17.43 require monitoring for sustainability amid market volatility.
Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.
Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
